Retractable Technologies, Inc. (RVP)

Retractable Technologies, Inc. experienced several stock-impacting events in the past six months. The company reported a net sales of $10.1 million for Q3 2025 with an operating loss of $3.7 million. A workforce reduction of approximately 7% was announced in July 2025. Dividend declarations were made for Series II and Series III Class B Convertible Preferred Stock. The EasyPoint® Blood Collection Tube Holder with Needle received an 'Innovative Technology' designation from Vizient. The CEO made multiple purchases of RVP common stock. Tariffs on imported needles and syringes continued to impact results. As of early February 2026, the stock was trading around $0.65.

Specific recurring seasonal patterns for the demand of Retractable Technologies, Inc.'s products are not explicitly detailed. The syringe and needle market is influenced by factors such as vaccination programs, and the increasing need for injectable medicines. The COVID-19 pandemic significantly boosted demand for syringes, but this was an extraordinary event rather than a typical seasonal pattern.

Retractable Technologies, Inc. (RVP) is a U.S.-based medical device company specializing in safety-engineered injection technologies to reduce needlestick injuries and prevent product reuse. They operate within the Healthcare sector, offering products like VanishPoint® syringes and blood collection sets, Patient Safe® syringes and Luer Caps, EasyPoint® needles, and IV safety catheters.

Retractable Technologies, Inc. distributes its products across the United States, the rest of North and South America, and internationally through a network of distributors. Domestic sales account for a significant majority of revenues, while international revenues increased by 38.1% for the nine months ended September 30, 2025. The company's headquarters and manufacturing facility are located in Little Elm, Texas.

Retractable Technologies has maintained a positive brand reputation, particularly through its focus on safety and innovation. The EasyPoint® Blood Collection Tube Holder with Needle received an 'Innovative Technology' designation from Vizient. Eight of the top 10 U.S. hospitals utilize its VanishPoint® technology.

Retractable Technologies, Inc. has 41 institutional owners and shareholders holding a total of 2,610,769 shares. Major institutional shareholders include Vanguard Group Inc. and Renaissance Technologies Llc. Thomas Shaw, the CEO, holds a significant stake of 55.66% of the equities, and Michele Larios holds 2.876%.